- Home
- ARCT vs OMER Comparison
ARCT vs OMER Comparison
Compare ARCT & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- OMER
- Stock Information
- Founded
- ARCT 2013
- OMER 1994
- Country
- ARCT United States
- OMER United States
- Employees
- ARCT N/A
- OMER N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- ARCT Health Care
- OMER Health Care
- Exchange
- ARCT Nasdaq
- OMER Nasdaq
- Market Cap
- ARCT 298.3M
- OMER 188.1M
- IPO Year
- ARCT N/A
- OMER 2009
- Fundamental
- Price
- ARCT $13.19
- OMER $3.07
- Analyst Decision
- ARCT Strong Buy
- OMER Strong Buy
- Analyst Count
- ARCT 8
- OMER 5
- Target Price
- ARCT $52.33
- OMER $18.00
- AVG Volume (30 Days)
- ARCT 497.0K
- OMER 889.1K
- Earning Date
- ARCT 08-04-2025
- OMER 08-06-2025
- Dividend Yield
- ARCT N/A
- OMER N/A
- EPS Growth
- ARCT N/A
- OMER N/A
- EPS
- ARCT N/A
- OMER N/A
- Revenue
- ARCT $143,680,000.00
- OMER N/A
- Revenue This Year
- ARCT N/A
- OMER N/A
- Revenue Next Year
- ARCT $34.79
- OMER $468.75
- P/E Ratio
- ARCT N/A
- OMER N/A
- Revenue Growth
- ARCT 15.38
- OMER N/A
- 52 Week Low
- ARCT $8.04
- OMER $2.97
- 52 Week High
- ARCT $25.88
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- ARCT 66.19
- OMER 39.87
- Support Level
- ARCT $12.03
- OMER $3.11
- Resistance Level
- ARCT $14.75
- OMER $3.60
- Average True Range (ATR)
- ARCT 0.79
- OMER 0.28
- MACD
- ARCT 0.20
- OMER 0.10
- Stochastic Oscillator
- ARCT 89.96
- OMER 22.11
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.